|
The Epigenetic Advance: CellCentric Licences Novel Discovery Programme to Takeda |
CellCentric, the world-leading epigenetics company based in Cambridge UK, has announced details of a significant deal, which takes epigenetic science closer towards clinical application and commercialisation in the field of cancer. The company has a considerable IP resource in novel epigenetic targets. It is from this portfolio that CellCentric has granted to Takeda Pharmaceutical Company Limited an exclusive licence to develop a key cancer programme. More details here. |
|
ABC Meeting: Cambridge Stem Cell Club: "Modelling, Marketing and Methyl Mysteries" |
|
EESCN's Academic, Business and Clinical Meeting for March presents new insights in epigenetics, techniques for staying ahead of the regulator and the undoubted opportunities of the third dimension. Thursday, 18th March 2010, Sanger Lecture Theatre, Tennis Court Road. For more information on this event, please see the Events page |
|
|
|
